Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines

被引:102
作者
Fukasawa, M
Korc, M
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA
[2] Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA
[3] Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA
关键词
D O I
10.1158/1078-0432.CCR-03-0820
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Vascular endothelial growth factor A (VEGF-A) is a potent angiogenic agent that binds to two high affinity VEGF receptors (VEGFRs), a process facilitated by the low affinity neuropilin receptors. Although VEGF-A is overexpressed in pancreatic ductal adenocarcinoma, it is not known whether the in vivo growth of multiple pancreatic cancer cells can be efficiently blocked by VEGF-A sequestration. Experimental Design: Four human pancreatic cancer cell lines were grown s.c. in athymic nude mice. One cell line also was used to generate an orthotopic model of metastatic pancreatic cancer. The consequences of VEGF-A sequestration on tumor growth and metastasis were examined by injecting the mice with a soluble VEGFR chimer (VEGF-Trap) that binds VEGF-A with high affinity. Results: VEGF-Trap, initiated 2 days after tumor cell inoculation, suppressed the s.c. growth of four pancreatic cancer cell lines and markedly decreased tumor microvessel density. Analysis of RNA from tumors generated with T3M4 cells revealed that VEGF-Trap decreased the expression of VEGFR-1 and neuropilin-1 and -2. VEGF-Trap, initiated 3 weeks after tumor implantation, also attenuated intrapancreatic tumor growth and metastasis in an orthotopic model using PANC-1 cells. Conclusions: VEGF-Trap is a potent suppressor of pancreatic tumor growth and metastasis and also may act to attenuate neuropilin-1 and -2 and VEGFR-1 expression. Therefore, VEGF-Trap may represent an exceedingly useful therapeutic modality for pancreatic ductal adenocarcinoma.
引用
收藏
页码:3327 / 3332
页数:6
相关论文
共 52 条
[1]  
Bachelder RE, 2001, CANCER RES, V61, P5736
[2]   Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas [J].
Bartsch, D ;
Barth, P ;
Bastian, D ;
Ramaswamy, A ;
Gerdes, B ;
Chaloupka, B ;
Deiss, Y ;
Simon, B ;
Schudy, A .
CANCER LETTERS, 1999, 139 (01) :43-49
[3]   Chemotherapeutic advances in pancreatic cancer [J].
Jordan D. Berlin ;
Mace L. Rothenberg .
Current Oncology Reports, 2003, 5 (3) :219-226
[4]   Radiation therapy in pancreatic cancer - Current practice and future trends [J].
Bodner, WR ;
Hilaris, BS ;
Mastoras, DA .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 30 (03) :230-233
[5]  
Byrne AT, 2003, CLIN CANCER RES, V9, P5721
[6]   VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition [J].
Dias, S ;
Shmelkov, SV ;
Lam, G ;
Rafii, S .
BLOOD, 2002, 99 (07) :2532-2540
[7]   VPF/VEGF and the angiogenic response [J].
Dvorak, HF .
SEMINARS IN PERINATOLOGY, 2000, 24 (01) :75-78
[8]   Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma [J].
Ellis, LM ;
Takahashi, Y ;
Fenoglio, CJ ;
Cleary, KR ;
Bucana, CD ;
Evans, DB .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (03) :337-340
[9]   Molecular and biological properties of vascular endothelial growth factor [J].
Ferrara, N .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (07) :527-543
[10]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31